Skin rash composition after checkpoint inhibitor therapy varies by therapeutic regimen
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
Patient skin rash and control cell counts.
应用场景：
创建时间：
2022-05-05
相关数据集
Supplementary materials of the article
This dataset includes the therapeutic approach distribution among immune checkpoint inhibitor-Induced Bullous pemphigoid subtypes and the initial corticosteroid dosage distribution charts for differen
Mendeley Data60
Immune-related cutaneous adverse events display distinct clinical and molecular characteristics, depending on immune checkpoints targeted
Background/Objectives: Immune-related cutaneous adverse events (ircAE) are common complications of cancer immunotherapy and provide insight into immune-related ad-verse events (irAE) more broadly. To
NIAID Data Ecosystem30
Tape Strip Profiling of Checkpoint Inhibitor-Associated Dermatitis Highlights Pan-T-Cell Activation: A Pilot Study
This pilot study examined gene expression in lesional and non-lesional tape strip samples obtained from 5 patients with immune-checkpoint inhibitor (ICI) eczematous reactions/ICI-Ecz, 3 patients with
NIAID Data Ecosystem30
Dermatology evaluation for cutaneous immune related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition: Supplemental File 1
This file includes additional details on study methodology.
Mendeley Data40
Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: a multicenter retrospective study.
Supplemental Table 1. Baseline characteristics of 42 patients with follicular reactions related to ICIs. Supplemental Table 2. Clinical differences between acneiform rash, papulopustular rosacea, fol
NIAID Data Ecosystem30
